MEDIC
Streamlined cancer drug target discovery/validation by CRISPR functional genomics in cancer organoid models at scale.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
* | $5.0m | Early VC | |
| Total Funding | 000k | ||
Related Content
MEDiC is a cutting-edge biotechnology startup focused on revolutionizing cancer drug development. The company operates in the oncology sector, specifically targeting the identification and utilization of cancer biomarkers—biological indicators that can help stratify patients for specific oncology drugs. Traditional drug development often overlooks many potential biomarkers and novel drug targets, but MEDiC aims to change that.
The company's proprietary platform integrates a tumor immune co-culture system with CRISPR technology. This advanced system allows MEDiC to systematically assess how cancer mutations contribute to tumor growth and how they respond to drugs or the immune system. Essentially, MEDiC's technology can identify how and why certain cancers resist treatment, which is crucial for developing more effective therapies.
MEDiC serves a diverse range of clients, including pharmaceutical companies, biotech firms, and research institutions. These clients are either interested in developing new oncology drugs or in identifying novel biomarkers for existing drugs, particularly those targeting drug-resistant cancer mutations.
The market MEDiC operates in is the global oncology drug development sector, which is a rapidly growing field due to the increasing prevalence of cancer and the ongoing need for more effective treatments. MEDiC's business model revolves around partnerships and collaborations. The company offers its platform for co-development programs and partnerships, allowing other entities to leverage MEDiC's technology to advance their own drug development efforts.
MEDiC generates revenue through these collaborative partnerships, as well as through licensing its technology and data. The company has already made significant strides, as evidenced by winning a prestigious prize for generating the most data among Illumina Accelerator genomics startups, producing a record 34 terabytes of whole-genome sequencing data from patient-derived cancer organoids.
Keywords: cancer biomarkers, oncology drugs, CRISPR, tumor immune system, drug resistance, biotechnology, drug development, partnerships, genomics, personalized medicine.